Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

Pfizer enters ADHD market with Quillivant XR launch

Gained rights last November as part of NextWave acquisition

- PMLiVE

Pfizer acquires spinal muscular atrophy research programme

Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

ViiV submits dolutegravir for approval to treat HIV in US, EU and Canada

GSK-Pfizer joint venture takes next step towards commercialisation

- PMLiVE

Guidance for local formularies in England could improve uptake

NICE publishes recommendations to address variations

- PMLiVE

Government wants Prof David Haslam to be new NICE chair

He would take over from Prof Sir Michael Rawlins in April

- PMLiVE

Eliquis meets targets as long-term VTE therapy

Pfizer and BMS report positive phase III data for the Factor Xa inhibitor

- PMLiVE

Pfizer set for negative NICE decision on Inlyta

Institute's draft guidance doesn't recommend drug for advanced kidney cancer

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

- PMLiVE

Pfizer reports strong data with new breast cancer candidate

Phase II results suggest progression-free survival benefits for PD-0332991

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links